Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL JAMES DOWNING

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1639159346
CMS profile
300554
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$327.48

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $327.48 15

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL JAMES DOWNING

NPI 1639159346 · CMS profile ID 300554

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1639159346?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $327.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $15.5112/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686585003 CMS
Neurocrine Biosciences, Inc. $18.1411/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693124787 CMS
Indivior Inc. $16.0410/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705775213 CMS
Alkermes, Inc. $12.1409/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686585005 CMS
Alkermes, Inc. $14.0608/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686585001 CMS
Janssen Pharmaceuticals, Inc $19.5708/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658527621 CMS
Indivior Inc. $12.0707/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705775211 CMS
JAZZ PHARMACEUTICALS INC. $12.7007/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684174127 CMS
Allergan Inc. $17.5207/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670271099 CMS
Indivior Inc. $20.1306/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705775209 CMS
Takeda Pharmaceuticals U.S.A., Inc. $99.4705/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682109013 CMS
Lundbeck LLC $12.3804/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684293419 CMS
Janssen Pharmaceuticals, Inc $25.0203/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658527615 CMS
Alkermes, Inc. $18.5803/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686584999 CMS
Allergan Inc. $14.1501/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670271096 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $327.48 15
PY2020 $163.49 9
PY2021 $551.28 27
PY2022 $399.89 22
PY2023 $626.73 20
PY2024 $647.99 23
PY2025 $847.36 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $914,450.61 88
PY2024 Recipient $2,949.66 2
PY2024 Principal investigator $1,362,460.91 98
PY2023 Recipient $59,611.81 14
PY2023 Principal investigator $997,596.68 181
PY2022 Principal investigator $897,046.39 115
PY2021 Principal investigator $714,455.57 113
PY2020 Principal investigator $1,352,717.69 219
PY2019 Recipient $157,177.13 20
PY2019 Principal investigator $1,373,636.72 268

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,814.31 12/31/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202534351
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202534371
Principal investigator 1 ABBVIE INC. $938.72 12/31/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies No dispute reported 06/30/2026 1202534373
Principal investigator 1 ABBVIE INC. $852.28 12/31/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS
Multicenter, Open-label Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202534375
Principal investigator 1 Eli Lilly and Company $12,116.14 12/16/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF BRENIPATIDE COMPARED WITH PLACEBO FOR REDUCTION IN RISK OF RELAPSE TO CIGARETTE SMOKING IN ADULTS (RENEW-SMK-1) No dispute reported 06/30/2026 1187882934
Principal investigator 1 Axsome Therapeutics, Inc. $15,489.66 12/11/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916600
Principal investigator 1 ABBVIE INC. $21,425.00 12/04/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202528908
Principal investigator 1 ABBVIE INC. $7,198.10 12/04/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202528910
Principal investigator 1 ABBVIE INC. $12,200.00 12/04/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LLC
Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202528912
Principal investigator 1 ABBVIE INC. $12,032.00 12/04/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LLC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202528914
Principal investigator 1 Axsome Therapeutics, Inc. $19,885.16 11/14/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916598
Principal investigator 1 PFIZER INC. $1,404.76 11/13/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1228818000
Principal investigator 1 PFIZER INC. $500.00 11/13/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1228818006
Principal investigator 1 ABBVIE INC. $4,390.20 11/05/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202522625
Principal investigator 1 ABBVIE INC. $18,449.60 11/05/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522629
Principal investigator 1 PFIZER INC. $2,928.00 10/30/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1228823438
Principal investigator 1 Axsome Therapeutics, Inc. $32,914.48 10/17/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916596
Principal investigator 1 ABBVIE INC. $15,663.78 10/09/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202514399
Principal investigator 1 ABBVIE INC. $30,809.35 10/09/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202514401
Principal investigator 1 PFIZER INC. $1,000.00 10/09/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1228823443
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $422.00 09/26/2025 Non-covered Recipient Entity
Futuresearch Trials Of Dallas Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067649
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,500.00 09/26/2025 Non-covered Recipient Entity
Futuresearch Trials Of Dallas Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067651
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,413.60 09/26/2025 Non-covered Recipient Entity
Futuresearch Trials Of Dallas Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067653
Principal investigator 1 Axsome Therapeutics, Inc. $44,058.35 09/15/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916594
Principal investigator 1 ABBVIE INC. $26,507.10 09/04/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LLC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202509824
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,194.00 09/03/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223284943
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $5,000.00 08/29/2025 Non-covered Recipient Entity
Futuresearch Trials Of Dallas Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067079
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $230.10 08/27/2025 Non-covered Recipient Entity
Futuresearch Trials Of Dallas Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067077
Principal investigator 1 Axsome Therapeutics, Inc. $36,986.55 08/13/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916592
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,800.00 08/06/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223283901
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,013.00 08/06/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223283903
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,025.00 08/06/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223283905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,620.00 08/06/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223283907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,038.00 08/06/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223283909
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,620.00 08/06/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223283911
Principal investigator 1 PFIZER INC. $3,000.00 07/25/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228841087
Principal investigator 1 Axsome Therapeutics, Inc. $60,742.75 07/23/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916590
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $4,488.00 07/11/2025 Non-covered Recipient Entity
Futuresearch Trials Of Dallas Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066987
Principal investigator 1 ABBVIE INC. $4,317.30 07/02/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202494039
Principal investigator 1 ABBVIE INC. $27,189.50 07/02/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202494041
Principal investigator 1 Axsome Therapeutics, Inc. $50,885.81 06/13/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916588
Principal investigator 1 Eli Lilly and Company $26,617.00 06/10/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187881442
Principal investigator 1 ABBVIE INC. $2,483.00 06/03/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202489815
Principal investigator 1 Axsome Therapeutics, Inc. $39,528.05 05/16/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916586
Principal investigator 1 ABBVIE INC. $13,691.60 05/07/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202483397
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,000.00 05/02/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
ITI-007-602 No dispute reported 06/30/2026 1242345705
Principal investigator 1 Eli Lilly and Company $2,262.90 04/30/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187882734
Principal investigator 1 Axsome Therapeutics, Inc. $65,557.60 04/16/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916584
Principal investigator 1 ABBVIE INC. $19,992.70 04/03/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202470249
Principal investigator 1 Axsome Therapeutics, Inc. $33,600.46 03/24/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916582
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,158.30 03/12/2025 Non-covered Recipient Entity
Futuresearch Trials Of Dallas Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067253
Principal investigator 1 Eli Lilly and Company $38.25 03/10/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187881766
Principal investigator 1 ABBVIE INC. $5,484.70 03/07/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202459623
Principal investigator 1 Eli Lilly and Company $223.77 03/05/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A PHASE 2, DOUBLE-BLIND, PROOF OF CONCEPT STUDY TO EVALUATE MAZDUTIDE COMPARED WITH PLACEBO IN PARTICIPANTS WITH ALCOHOL USE DISORDER No dispute reported 06/30/2026 1187881666
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 03/01/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646521
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 03/01/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646523
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 02/25/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646525
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 02/25/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646527
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 02/25/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646529
Principal investigator 1 Boehringer Ingelheim International GmbH $42.80 02/25/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646531
Principal investigator 1 Axsome Therapeutics, Inc. $25,734.03 02/18/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916580
Principal investigator 1 ABBVIE INC. $9,932.00 02/06/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202446943
Principal investigator 1 PFIZER INC. $99.00 02/06/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1228859040
Principal investigator 1 PFIZER INC. $626.50 02/06/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1228860049
Principal investigator 1 Eli Lilly and Company $29,310.00 02/04/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187881094
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 02/01/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646511
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 02/01/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646513
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646515
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646517
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 02/01/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646519
Principal investigator 1 Eli Lilly and Company $5,160.06 01/31/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187884088
Principal investigator 1 PFIZER INC. $5,771.23 01/30/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1228860056
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,376.00 01/29/2025 Non-covered Recipient Entity
Futuresearch Trials Of Dallas Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067583
Principal investigator 1 PFIZER INC. $1,242.60 01/23/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228859047
Principal investigator 1 Eli Lilly and Company $794.28 01/21/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187880009
Principal investigator 1 Eli Lilly and Company $14,032.00 01/21/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187882730
Principal investigator 1 Eli Lilly and Company $2,200.18 01/20/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187881764
Principal investigator 1 Axsome Therapeutics, Inc. $8,017.77 01/14/2025 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199916578
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,941.30 01/14/2025 Non-covered Recipient Entity
Futuresearch Trials Of Dallas Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067581
Principal investigator 1 Eli Lilly and Company $1,327.27 01/09/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187883080
Principal investigator 1 Eli Lilly and Company $4,760.88 01/09/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187883082
Principal investigator 1 Eli Lilly and Company $68,123.00 01/07/2025 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187883078
Principal investigator 1 Sage Therapeutics, LLC $10,570.50 01/06/2025 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 1206580651
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646503
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646505
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646507
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646509
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 01/01/2025 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1220646533